175250.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 1.17, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.59, suggesting limited short-term liquidity to cover immediate liabilities. The company's cash and equivalents amount to 8,269,965,480 KRW, but this is significantly lower than its long-term debt of 30,717,907,670 KRW, resulting in a negative net cash position.

Profitability metrics are weak, with a return on equity of -1.2754 and a return on assets of -0.3713, both significantly below the industry median for pharmaceutical companies. The company reported a net loss of 33,600,111,690 KRW and an operating loss of 24,396,747,710 KRW, indicating a challenging operating environment and potential cost overruns or pricing pressures.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory risks. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets.

The company's growth trajectory is negative, with a net loss and declining operating performance. The outlook for the current fiscal year is not explicitly provided, but the reported financials suggest a continuation of the current trend. The company's capital expenditures of 5,478,434,750 KRW were not sufficient to offset the negative cash flows from operations, resulting in a free cash flow of -34,013,378,510 KRW.

The company's risk profile is elevated, with a medium liquidity risk and a negative net cash position. The risk assessment indicates a low probability of dilution, but the company's financial performance and liquidity constraints could lead to future capital-raising activities. The absence of a detailed risk management strategy in the available data raises concerns about the company's ability to navigate financial stress.

No recent events, such as filings or transcripts, are available in the provided data to provide additional context on the company's operations or strategic direction. The lack of recent disclosures limits the ability to assess the company's response to market conditions or regulatory changes.